Adcock Ingram and Aspen Pharmacare have won a share of the government's HIV/AIDS drugs contract. Picture: REUTERS/SUKREE SUKPLANG
Adcock Ingram and Aspen Pharmacare have won a share of the government's HIV/AIDS drugs contract. Picture: REUTERS/SUKREE SUKPLANG

Steven Schultz from Momentum chose Aspen Pharmacare as his stock pick of the day.

“It’s Aspen, it’s a counter that’s effectively halved in value over the past 12 months. There have been a number of reasons why, most notably debt build-up and shareholders are obviously uncomfortable with that.”

Or listen to the full audio: